Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease - PubMed

Review

Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease

C Hischenhuber et al. Aliment Pharmacol Ther. 2006.

Abstract

For both wheat allergy and coeliac disease the dietary avoidance of wheat and other gluten-containing cereals is the only effective treatment. Estimation of the maximum tolerated amount of gluten for susceptible individuals would support effective management of their disease. Literature was reviewed to evaluate whether an upper limit for gluten content in food, which would be safe for sufferers from both diseases, could be identified. When setting gluten limits for coeliac disease sufferers, the overall potential daily intake should be considered, while for wheat allergy limits should be based on single servings. For coeliac disease sufferers this limit should lie between 10 and 100 mg daily intake. For wheat allergy, lowest eliciting doses for children lie in the lower milligram range, while for adults they are most significantly higher. Gliadins (part of the gluten proteins) not only trigger coeliac disease, but are also major allergens in wheat allergy. Therefore, measurement of gliadins with validated enzyme-linked immunosorbent assay methods provides an appropriate marker for assessing gluten and/or wheat protein contents in food. Available data suggest that a maximum gluten content for 'gluten-free' foods could be set, which protects both wheat allergy sufferers and coeliac patients.

Similar articles

• Innovative approach to low-level gluten determination in foods using a novel sandwich enzyme-linked immunosorbent assay protocol.

  Valdés I, García E, Llorente M, Méndez E. Valdés I, et al. Eur J Gastroenterol Hepatol. 2003 May;15(5):465-74. doi: 10.1097/01.meg.0000059119.41030.df. Eur J Gastroenterol Hepatol. 2003. PMID: 12702901

• No induction of anti-avenin IgA by oats in adult, diet-treated coeliac disease.

  Guttormsen V, Løvik A, Bye A, Bratlie J, Mørkrid L, Lundin KE. Guttormsen V, et al. Scand J Gastroenterol. 2008;43(2):161-5. doi: 10.1080/00365520701832822. Scand J Gastroenterol. 2008. PMID: 18224563 Clinical Trial.

• Wheat starch, gliadin, and the gluten-free diet.

  Thompson T. Thompson T. J Am Diet Assoc. 2001 Dec;101(12):1456-9. doi: 10.1016/S0002-8223(01)00351-0. J Am Diet Assoc. 2001. PMID: 11762742

• The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease?

  Collin P, Thorell L, Kaukinen K, Mäki M. Collin P, et al. Aliment Pharmacol Ther. 2004 Jun 15;19(12):1277-83. doi: 10.1111/j.1365-2036.2004.01961.x. Aliment Pharmacol Ther. 2004. PMID: 15191509 Review.

• Proteomic analysis in allergy and intolerance to wheat products.

  Mamone G, Picariello G, Addeo F, Ferranti P. Mamone G, et al. Expert Rev Proteomics. 2011 Feb;8(1):95-115. doi: 10.1586/epr.10.98. Expert Rev Proteomics. 2011. PMID: 21329430 Review.

Cited by

• Celiac disease: understanding the gluten-free diet.

  Bascuñán KA, Vespa MC, Araya M. Bascuñán KA, et al. Eur J Nutr. 2017 Mar;56(2):449-459. doi: 10.1007/s00394-016-1238-5. Epub 2016 Jun 22. Eur J Nutr. 2017. PMID: 27334430 Review.

• AllerCatPro-prediction of protein allergenicity potential from the protein sequence.

  Maurer-Stroh S, Krutz NL, Kern PS, Gunalan V, Nguyen MN, Limviphuvadh V, Eisenhaber F, Gerberick GF. Maurer-Stroh S, et al. Bioinformatics. 2019 Sep 1;35(17):3020-3027. doi: 10.1093/bioinformatics/btz029. Bioinformatics. 2019. PMID: 30657872 Free PMC article.

• Enzymatic strategies to detoxify gluten: implications for celiac disease.

  Caputo I, Lepretti M, Martucciello S, Esposito C. Caputo I, et al. Enzyme Res. 2010 Oct 7;2010:174354. doi: 10.4061/2010/174354. Enzyme Res. 2010. PMID: 21048862 Free PMC article.

• Effective Degradation of Gluten and Its Fragments by Gluten-Specific Peptidases: A Review on Application for the Treatment of Patients with Gluten Sensitivity.

  Dunaevsky YE, Tereshchenkova VF, Belozersky MA, Filippova IY, Oppert B, Elpidina EN. Dunaevsky YE, et al. Pharmaceutics. 2021 Oct 2;13(10):1603. doi: 10.3390/pharmaceutics13101603. Pharmaceutics. 2021. PMID: 34683896 Free PMC article. Review.

• Scientific Opinion related to a notification from Lyckeby Starch AB on barley starch to be used in the manufacturing of several foods as ingredient, of the food additive modified starch and of glucose syrups pursuant to Article 21(2) of Regulation (EU) No 1169/2011 - for permanent exemption from labelling.

  EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Castenmiller J, Hirsch Ernst KI, Kearney J, Knutsen HK, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Marchelli R, van Loveren H, Martínez SV, de Henauw S. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al. EFSA J. 2020 May 15;18(5):e06118. doi: 10.2903/j.efsa.2020.6118. eCollection 2020 May. EFSA J. 2020. PMID: 37649494 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information